Khalid Halahleh, Suhaib Al Sawajneh, Yacob Saleh, Omar Shahin, Alaa Abufara, Mohamad Ma'koseh, Rashid Abdel-Razeq, Fareed Barakat, Hadeel Abdelkhaleq, Nadira Al-Hassan, Reem Atiyyat, Noor Al-Faker, Zaid Omari, Hamza Ghatasheh, Imad Jaradat, Isa Muradi, Sultan Iyad, Ali Bazarbachi
INTRODUCTION: Checkpoint inhibitors demonstrated significant efficacy in relapsed/refractory Hodgkin's Lymphoma (R/R cHL) resulting in high responses and prolonged progression free survival in patients, who relapse after or are ineligible for autologous stem cell transplantation (auto-SCT). We aimed to assess the efficacy and toxicity of Pembrolizumab before auto-SCT and in transplant naïve patients and calculate survival outcomes. PATIENTS AND METHODS: Fifty-five patients with R/R cHL were included...
March 4, 2022: Clinical Lymphoma, Myeloma & Leukemia